Mark Angel, MD
Interventional Cardiology · Willoughby, OHNPI 1154315661
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $425 and has fallen 54.2% since, to $195 in 2025. That places this record below the midpoint for interventional cardiology clinicians in OH, where the typical reported total is $4,547.
Across 69 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$335
- Novartis$268
- Abbott$196
- Medtronic$188
- Johnson & Johnson$88
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$70
- plus $575 from 17 others
What the payments were for
- Food & beverage$1,720100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 5 | $335 |
| Novartis | 13 | $268 |
| Abbott | 5 | $196 |
| Medtronic(2 entities) | 7 | $188 |
| Johnson & Johnson | 5 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $70 |
| Biotronik Inc. | 1 | $64 |
| AstraZeneca | 4 | $64 |
| Abiomed | 2 | $51 |
| Philips North America LLC | 2 | $45 |
| Cardiva Medical, Inc. | 1 | $42 |
| Amgen | 3 | $39 |
| Pfizer | 3 | $36 |
| Cordis US CORP. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Atricure, Inc. | 1 | $23 |
| Teleflex LLC | 1 | $21 |
| Surmodics, Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Asahi Intecc USA, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$187
- MitraClip$117
How this compares
$1,720 in reported general payments places this provider in the 25th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $169,527 |
| EntrestoSacubitril/Valsartan | 71 | $89,987 |
| XareltoRivaroxaban | 34 | $42,133 |
| FarxigaDapagliflozin Propanediol | 17 | $12,628 |
| JardianceEmpagliflozin | 12 | $12,032 |
| Repatha SureclickEvolocumab | 11 | $10,978 |
| Atorvastatin Calcium | 560 | $5,514 |
| Metoprolol Succinate | 358 | $5,374 |
| ClopidogrelClopidogrel Bisulfate | 275 | $2,939 |
| Rosuvastatin Calcium | 141 | $2,065 |
| Ezetimibe | 60 | $1,492 |
| Carvedilol | 159 | $1,443 |
| Amlodipine Besylate | 134 | $868 |
| Lisinopril | 126 | $865 |
| Metoprolol Tartrate | 149 | $798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $169,527145 claims |
| NovartisEntresto | $268 | $89,98771 claims |
| Johnson & JohnsonXarelto | $88 | $42,13334 claims |
| AstraZenecaFarxiga | $64 | $12,62817 claims |
| Boehringer IngelheimJardiance | $14 | $12,03212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Willoughby
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.